CoChat

2´-Deoxy Purine, 2´-O-Methyl Pyrimidine (dRmY) Aptamers as Candidate Therapeutics

Burmeister, Paula E., Wang, Chunhua, Killough, Jason R., Lewis, Scott D., Horwitz, Lillian R., Ferguson, Alicia, Thompson, Kristin M., Pendergrast, P. Shannon, McCauley, Thomas G., Kurz, Markus, Diener, John, Cload, Sharon T., Wilson, Charles, Keefe, Anthony D. · 2006 · Oligonucleotides
Cited by 64

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Aptamers are short oligonucleotides that fold into well-defined three-dimensional architectures thereby enabling specific binding to molecular targets such as proteins. To be successful as a novel therapeutic modality, it is important for aptamers to not only bind their targets with high specificity and affinity, but also to exhibit favorable properties with respect to in vivo stability, cost-effective synthesis, and tolerability (i.e., safety). We describe methods for generating aptamers comprising 2 - deoxy purines and 2 -O-methyl pyrimidines (dRmY) that broadly satisfy many of these additional constraints. Conditions under which dRmY transcripts can be efficiently synthesized using mutant T7 RNA polymerases have been identified and used to generate large libraries from which dRmY aptamers to multiple target proteins, including interleukin (IL)-23 and thrombin, have been successfully discovered using the SELEX process. dRmY aptamers are shown to be highly nuclease-resistant, long-lived in vivo, efficiently synthesized, and capable of binding protein targets in a manner that inhibits their biologic activity with K(D) values in the low nM range. We believe that dRmY aptamers have considerable potential as a new class of therapeutic aptamers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/oli.2006.16.337

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Effect of pegylation on pharmaceuticals

    Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 1×

    “…mechanism for nuclease-stabi-lized oligonucleotides administered intravenously, PEG conjugation is a widely used strategy for prolonging residence times of peptide and protein drugs, see for example Sheffield (2001), Caliceti and Veronese (2003), Harris and Chess (2003), and Molineux (2003).”
  • Pegaptanib for neovascular age-related macular degeneration

    Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×

    “…endothelial growth factor (VEGF) aptamer, was recently approved for therapeutic use for the treatment of age-related macular degeneration, a progressive disease that is the leading cause of blindness in the elderly (Gragoudas et al., 2004; Moshfeghi and Puli-afito, 2005; Ruckman et al., 1998).”
  • Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation

    Murphy, C. A., Langrish, C. L., Chen, Y., Blumenschein, W., McClanahan, T., Kastelein, R. A., Sedgwick, J. D., & Cua, D. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030896 · Cited by 1,669

Show all 3 references

Cited by

Metadata

Authors
Burmeister, P. E., Wang, C., Killough, J. R., Lewis, S. D., Horwitz, L. R., Ferguson, A., Thompson, K. M., Pendergrast, P. S., McCauley, T. G., Kurz, M., Diener, J., Cload, S. T., Wilson, C., & Keefe, A. D.
Venue
Oligonucleotides
Published
2006-12
Volume
16
Issue
4
Pages
337-351
ISSN
  • 1545-4576 (ISSN-L)
  • 1557-8526
OpenAlex
W2112219877
Cited by
64
References
3
FWCI
0.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.